Zobrazeno 1 - 10
of 167
pro vyhledávání: '"A E Lykkesfeldt"'
Autor:
Sanne Løkkegaard, Daniel Elias, Carla L. Alves, Martin V. Bennetzen, Anne-Vibeke Lænkholm, Martin Bak, Morten F. Gjerstorff, Lene E. Johansen, Henriette Vever, Christina Bjerre, Tove Kirkegaard, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Linda S. Lindström, Laura J. Esserman, Anne E. Lykkesfeldt, Jens S. Andersen, Rikke Leth-Larsen, Henrik J. Ditzel
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-15 (2021)
Abstract Resistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer is a major clinical problem with poorly understood mechanisms. There is an unmet need for prognostic and predictive biomarkers to allow appropriate therapeutic
Externí odkaz:
https://doaj.org/article/c7b5ad6a5a674cfcb8ece9f12b5c68d6
Autor:
Bo Wang, Dongping Li, Rocio Rodriguez-Juarez, Allison Farfus, Quinn Storozynsky, Megan Malach, Emily Carpenter, Jody Filkowski, Anne E. Lykkesfeldt, Olga Kovalchuk
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-13 (2018)
Abstract Background Breast cancer is the most common malignancy in women worldwide. Although the endocrine therapy that targets estrogen receptor α (ERα) signaling has been well established as an effective adjuvant treatment for patients with ERα-
Externí odkaz:
https://doaj.org/article/180db70a04884cc1b52d78dcc9f021ae
Autor:
Stephen R.D. Johnston, Mitch Dowsett, Lesley-Ann Martin, Anne E. Lykkesfeldt, Sunil Pancholi, Simone Detre, Suzanne Drury, Alexandra F. Leary
Supplementary Data from Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine Resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c8b40269c9aa7cd9c3acf817ce306b4
https://doi.org/10.1158/1078-0432.22439824.v1
https://doi.org/10.1158/1078-0432.22439824.v1
Autor:
Henrik J. Ditzel, Anne E. Lykkesfeldt, Tove Kirkegaard, Martin Bak, Maria Lyng, Daniel Elias, Carla L. Alves
Parallel micrographs of FFPE fulvestrant-resistant and parental breast cancer cell lines and clinical metastatic samples exhibiting comparable CDK6 levels.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ad72499404237dafe9ddb4b5fd7448c
https://doi.org/10.1158/1078-0432.22456619.v1
https://doi.org/10.1158/1078-0432.22456619.v1
Autor:
Henrik J. Ditzel, Anne E. Lykkesfeldt, Tove Kirkegaard, Martin Bak, Maria Lyng, Daniel Elias, Carla L. Alves
Purpose: Resistance to endocrine therapy in estrogen receptor–positive (ER+) breast cancer remains a major clinical problem. Recently, the CDK4/6 inhibitor palbociclib combined with letrozole or fulvestrant was approved for treatment of ER+ advance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6452d416372be503b091cfc914b765a1
https://doi.org/10.1158/1078-0432.c.6523370
https://doi.org/10.1158/1078-0432.c.6523370
Autor:
Henrik J. Ditzel, Anne E. Lykkesfeldt, Tove Kirkegaard, Martin Bak, Maria Lyng, Daniel Elias, Carla L. Alves
ER status in primary tumors and metastasis of ER+ advanced breast cancer patients treated or not with fulvestrant in the advanced disease setting.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cfb32a617899c1eb6a65115c4bce12f
https://doi.org/10.1158/1078-0432.22456604
https://doi.org/10.1158/1078-0432.22456604
Autor:
Stephen R.D. Johnston, Mitch Dowsett, Lesley-Ann Martin, Anne E. Lykkesfeldt, Sunil Pancholi, Simone Detre, Suzanne Drury, Alexandra F. Leary
CCR Translation for this Article from Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine Resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22a1b2cb0de2eb4edd56c0b97bdae4ce
https://doi.org/10.1158/1078-0432.22439827
https://doi.org/10.1158/1078-0432.22439827
Autor:
Stephen R.D. Johnston, Mitch Dowsett, Lesley-Ann Martin, Anne E. Lykkesfeldt, Sunil Pancholi, Simone Detre, Suzanne Drury, Alexandra F. Leary
Purpose: Acquired endocrine resistance in estrogen receptor (ER)α+/human epidermal growth factor receptor 2–negative (HER2−) breast cancer has been associated with modest adaptive increases in HER2, although exactly how aberrant HER2 signaling a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71575aa5be48efffeef9bfefeaa0e357
https://doi.org/10.1158/1078-0432.c.6517234.v1
https://doi.org/10.1158/1078-0432.c.6517234.v1
Autor:
Henrik J. Ditzel, Anne E. Lykkesfeldt, Tove Kirkegaard, Martin Bak, Maria Lyng, Daniel Elias, Carla L. Alves
Legends to Supplementary Figures S1-S3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a7f04b84d76c494042b0503313908c3
https://doi.org/10.1158/1078-0432.22456616.v1
https://doi.org/10.1158/1078-0432.22456616.v1
Autor:
Sarah L Larsen, Anne-Vibeke Laenkholm, Anne Katrine Duun-Henriksen, Martin Bak, Anne E Lykkesfeldt, Tove Kirkegaard
Publikováno v:
PLoS ONE, Vol 10, Iss 2, p e0118346 (2015)
The underlying mechanisms leading to antiestrogen resistance in estrogen-receptor α (ER)-positive breast cancer is still poorly understood. The aim of this study was therefore to identify biomarkers and novel treatments for antiestrogen resistant br
Externí odkaz:
https://doaj.org/article/71457a8fb2bc48c4ba9eea389e1fe2d1